Loading
Invented BH3 profiling, the functional test behind venetoclax's success, before becoming NCI director.
Anthony Letai is Director of the National Cancer Institute, having previously worked as a haematologist-scientist at Dana-Farber. He is known for inventing BH3 profiling, a functional test that measures mitochondrial apoptotic priming and predicts response to BCL-2 inhibitors such as venetoclax in acute myeloid leukaemia and chronic lymphocytic leukaemia. His selected paper shows that pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Appointed NCI director in 2025, he brought to the role a career in functional precision medicine and ex vivo drug testing.
| Title | Journal | Year |
|---|---|---|
| Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy | Science | 2011 |
Shares Intrinsic apoptosis (BCL-2 family), BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
Shares Intrinsic apoptosis (BCL-2 family), BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
Shares BCL-2, Venetoclax, Acute myeloid leukaemia.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia.